| Dozent: | Prof. Dr. Hans A. Kestler |
| Prof. Dr. Enno Ohlebusch | |
| Dr. Karlheinz Holzmann | |
| mit M. Sc. Robin Szekely | |
| Code |
CS6012.000
|
Vorlesungsbeginn ist am 17.10.2018
Die erste Übung (Einführung in R und Ausgabe des ersten Übungsblatts) findet am 26.10.2018 statt
Die Besichtigung der Core Facility Genomics findet am 09.01.2019 statt. Treffpunkt ist um 8:30 in O27, 123.
Die Vorlesung am 30.01.2019 entfällt krankheitsbedingt. Die Übung am 01.02.2019 findet aber regulär statt.
Die Klausureinsicht zur ersten Klausur findet am 15.03.2019, 15:00-16:00 in O27/5116 (Besprechungsraum) statt.
Die Klausureinsicht zur Nachklausur findet am 03.05.2019, 09:30-10:30 in O27/548 statt.
Mittwochs 08:30 - 10:00 Uhr, O27, 123
Freitags 14:00 - 16:00 Uhr, O27, 121, ab 26.10.2018 alle zwei Wochen
normal_vs_prostate_tumor.RData
Erster Termin: 26.02.2019, 10:00-11:30 Uhr, O27/H20
Zweiter Termin: 09.04.2019, 10:00-11:30 Uhr, N25/H8
The position paper "Is there a role for statistics in artificial intelligence" has been published online first in Advances in Data Analysis and Classification.
Our paper "Corona Health - A Study- and Sensor-Based Mobile App Platform Exploring Aspects of the COVID-19 Pandemic" has been published in the International Journal of Environmental Research and Public Health.
Our paper "Patient empowerment during the COVID-19 pandemic: Ensuring safe and fast communication of test results" has been published in the Journal of Medical Internet Research.
Our paper "Perspective on mHealth Concepts to Ensure Users’ Empowerment–From Adverse Event Tracking for COVID-19 Vaccinations to Oncological Treatment" has been published in IEEE Access.
Our paper "Capturing dynamic relevance in Boolean networks using graph theoretical measures" has been published online first in Bioinformatics.
Our report protocol "Digitalization of adverse event management in oncology to improve treatment outcome—A prospective study protocol" has been published in PLoS One.
We are happy we could contribute to Beutel et al (2021) "A prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response" published in MDPI Cancers.